Welcome to our dedicated page for Edwards Lifesciences SEC filings (Ticker: EW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Edwards Lifesciences Corporation filings document regulatory disclosures for a Delaware medical technology company with common stock listed on the New York Stock Exchange under EW. Recent Form 8-K reports furnish quarterly and annual operating results, including sales commentary tied to transcatheter aortic valve replacement and transcatheter mitral and tricuspid therapies.
Proxy and material-event filings cover board elections, executive compensation, shareholder voting results, amendments to the Long-Term Stock Incentive Compensation Program, and senior finance leadership changes. These records also identify the company’s registered common stock structure and formal governance matters submitted to stockholders.
Edwards Lifesciences Corp executive Daveen Chopra reported routine equity compensation activity involving performance-based restricted stock units. Chopra exercised performance rights covering 13,583 shares of common stock, linked to awards granted on May 11, 2023 with three-year performance vesting.
In connection with vesting, 7,538 shares of common stock were disposed of to cover tax obligations at a price of $79.96 per share, rather than through an open-market sale. Following these transactions, Chopra holds 45,824 shares of Edwards Lifesciences common stock directly.
The board’s Compensation and Governance Committee previously determined that 167.70% of the target number of performance-based units would vest as of May 11, 2026, and this Form 4 reflects the resulting share delivery and tax-withholding disposition.
Edwards Lifesciences Corporation submitted a Form 144 notice reporting proposed sales tied to recent equity-compensation vesting events. The filing lists restricted stock lapses on 05/03/2026 (523 shares), 05/07/2026 (4,222 shares), 05/08/2026 (5,489 shares) and a PSU/RSU entry on 05/11/2026 (26,640 shares). The filing also records a prior sale of 22,430 shares for $1,719,742.00 on 02/12/2026.
Edwards Lifesciences Corp Chief Financial Officer Scott B. Ullem reported compensation-related equity transactions tied to performance-based restricted stock units. On May 11, 2026, he exercised 19,830 Performance Rights into the same number of common shares following the Compensation and Governance Committee’s decision that 167.70% of the target units would vest.
To cover tax obligations, 11,004 common shares were disposed of through a tax-withholding transaction at $79.96 per share, rather than via an open-market sale. After these transactions, he directly holds 46,740 common shares and indirectly holds 266,318 common shares through a trust. The Performance Rights exercised in this filing are now fully converted, with no remaining derivative position from this award.
Edwards Lifesciences Corp executive Wayne Markowitz, CVP, JAPAC, reported a mix of share sales and new equity awards. He completed an open-market sale of 593 shares of common stock at $79.73 per share on May 11, 2026, and held 21,679.8708 shares afterward.
On May 7, 2026, he received 5,200 restricted stock units and separate 5,200 performance-based restricted stock units under the Long-Term Stock Incentive Compensation Program, plus 26,400 employee stock options with a $82.76 exercise price, all vesting in installments starting one year after grant.
On May 7 and May 8, a total of 490 shares of common stock were disposed of as tax-withholding transactions related to equity compensation, rather than open-market sales.
Edwards Lifesciences CEO Bernard J. Zovighian reported multiple equity compensation and routine share transfers. On May 7, 2026, he received 43,800 restricted stock units and 43,800 performance-based stock units under the company’s Long-Term Stock Incentive Compensation Program, plus options for 245,300 shares of common stock at an exercise price of $82.76 per share.
The time-based restricted stock units are scheduled to vest in four equal annual installments starting one year after grant, while the performance units are scheduled to vest on May 7, 2029 based on three-year performance goals. On the same date, options are scheduled to vest in 36 approximately equal monthly installments beginning one month after grant.
He also reported bona fide gifts totaling 19,422 shares and tax-withholding dispositions totaling 9,551 shares between May 7–11, 2026. After these transactions, he holds 104,795.6499 shares directly, 21,750.5511 shares indirectly through a trust, and 3,733.5603 shares indirectly via a 401(k) plan.
Edwards Lifesciences Corp executive Daniel J. Lippis reported a small tax-related share disposition. On May 11, 2026, 362 shares of common stock were disposed of at $79.96 per share to cover tax obligations. After this non-market transaction, he directly holds about 40,410.91 shares.
Edwards Lifesciences Corporation submitted a Rule 144 notice reporting proposed transactions in Common stock. The form lists 47,280.00 (reported figure) and a separate numeric entry 575,800,000. It also shows restricted stock lapse events of 19 shares on 05/07/2025 and 574 shares on 05/07/2026.
VALERIANI NICHOLAS J reported acquisition or exercise transactions in this Form 4 filing.
Edwards Lifesciences Corp director Nicholas J. Valeriani received 5,127 restricted stock units as equity compensation. The award was granted on May 8, 2026 under the company’s 2020 Nonemployee Directors Stock Incentive Program and will become fully vested after one year from the grant date or at the next annual stockholders’ meeting, whichever comes first. Following this grant, he directly holds 84,423 shares of common stock. This is a non-cash, routine director compensation grant rather than an open-market share purchase.
Edwards Lifesciences Corp director Ramona Sequeira reported an equity award and updated holdings. She received a grant of 3,251 shares of Common Stock in the form of restricted stock units at a price of $0.00 per share, classified as a grant/award acquisition. After this grant, her directly held common stock position is 6,779 shares.
The filing also shows an indirect holding of 14,076 shares of Common Stock held by trust. According to the grant terms, these restricted stock units were awarded on May 8, 2026 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program and are scheduled to become 100% vested after the earlier of one year from the grant date or the company’s next annual meeting of stockholders.
LORANGER STEVEN R reported acquisition or exercise transactions in this Form 4 filing.
Edwards Lifesciences director Steven R. Loranger reported equity awards and updated holdings. On May 8, 2026, he received 1,064 restricted stock units and a 3,251-share restricted stock award at $0.00 per share under the 2020 Nonemployee Directors Stock Incentive Program. Both awards are scheduled to vest 100% after the earlier of one year from the grant date or the company’s next annual stockholders’ meeting. Following these grants, he directly holds 8,997 shares and indirectly holds 75,372 shares through a trust.